Compounded tirzepatide recall pulls 22 lots over sterility doubts

A compounding pharmacy in Cary, North Carolina, has recalled 22 lots of injectable tirzepatide because it could not assure the vials were sterile. The compounded tirzepatide recall, classified Class II by the FDA on 8 October 2026, covers vials sent to customers across the United States by Apothecary Pharma. Tirzepatide is the active ingredient in Eli Lilly's Zepbound and Mounjaro, and compounded copies of it are sold widely through telehealth services. The recall is small in volume, but it lands in the middle of a long fight over whether those copies should be made at all.

What Apothecary Pharma recalled

The FDA enforcement report behind the compounded tirzepatide recall lists Apothecary Pharma LLC of Cary as the recalling firm and gives the reason in four words: lack of assurance of sterility. The product is tirzepatide injection in a sterile multi-dose vial, sold on prescription only. Twenty-two lots are named, each matched to a beyond-use date between 7 October and 26 November 2026, and the report counts one vial per lot. A second entry under the same event covers a single lot of an NAD+ injection made at the same address. The firm started the recall itself on 24 September, which makes it voluntary, and the report describes distribution as nationwide. The FDA classified it on 8 October, published it in the weekly enforcement report on 14 October and lists its status as ongoing.

A Class II label sits in the middle of the agency's three levels. As BioPharma Dive summarised the FDA definition, use of the product "may cause temporary or medically reversible adverse health consequences" or carries only a remote chance of serious harm. Class I is kept for products that could cause serious injury or death, and Class III for problems unlikely to hurt anyone. The entry gives a reason and a list of lots, but it does not say how the sterility doubt came to light, whether testing found contamination or whether any patient reported a problem. That gap is common in recall notices, which record what a firm and the agency agreed to do rather than the full story behind the decision. More detail may come if the FDA inspects the site.

Why sterility matters for an injection

Medicines that go under the skin skip the body's first defences, so a vial has to be free of living microbes before anyone draws a dose from it. Approved injectable drugs reach that standard through validated manufacturing that the FDA reviews before launch and inspects afterwards. Compounded drugs follow a different path. The agency's guidance for telehealth firms states that "compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing," and the FDA explains this in its notice to telehealth companies about promoting such products. A pharmacy can still make sterile products well, but nobody outside the pharmacy checks each batch before it ships.

Twenty-two lots are named, each matched to a beyond-use date between 7 October and 26 November 2026, and the report counts one vial per lot.

Multi-dose vials add a second layer of risk because the same container is punctured again and again over days or weeks. Each puncture is a chance to bring in bacteria, which is why such vials usually carry preservatives and strict beyond-use dates. When a pharmacy cannot show that a batch started out sterile, it cannot rule out that the problem grew with every use. A finding of lack of assurance of sterility does not prove that a vial was contaminated. It means the records or the process could not prove that it was clean, and for an injected product that uncertainty is treated as a defect on its own. Regulators treat a missing proof of sterility as seriously as a confirmed fault, because the patient has no way to test a vial at home.

Compounded GLP 1 copies after the shortage

Compounded GLP-1 products spread when demand for Zepbound and Novo Nordisk's Wegovy outran supply and both drugs sat on the FDA shortage list. During a shortage, federal rules let pharmacies make copies of a listed drug. Those shortages have since ended, as our report on how the semaglutide shortage was declared over explained, and the window for routine copies closed with them. Many sellers kept going by offering personalised versions, which federal law can allow when a prescriber decides a patient needs a change from the approved product. BioPharma Dive reported that a recent Gallup survey found about 20% of Americans taking these medicines use compounded forms.

Lilly and Novo have answered with lawsuits and public warnings, arguing that the quality and safety of compounded versions cannot be guaranteed. The trade press reports that the market now also includes copies of retatrutide, a Lilly medicine that has not been approved anywhere. The compounded tirzepatide recall gives the two companies a concrete case to point to, although one pharmacy's sterility lapse says little on its own about the wider market. It does show the limits of oversight: the problem was found and reported by the firm itself, and the public record arrived about three weeks after the recall began. For readers comparing products, the more useful fact is that an approved pen and a compounded vial reach patients through two very different checks.

What patients and prescribers can check

The FDA entry lists every affected lot number with its beyond-use date, so a patient who holds a vial from this pharmacy can compare the label with the list and ask the dispensing pharmacy or prescriber what to do next. Anyone who notices redness, swelling, fever or pain where they injected after using a vial from a recalled lot should contact a clinician, and problems can be reported to the FDA MedWatch program. Prescribers who route patients through telehealth services may want to ask which pharmacy fills the prescription, because the brand on a website is often not the firm that compounds the drug. None of this is medical advice, and this story does not recommend any product or seller.

The recall also arrives while regulators are rethinking which peptides pharmacies may compound at all. In July 2026 an FDA advisory committee narrowly recommended adding BPC-157, TB-500, KPV, MOTS-c, epitalon and semax to the list of bulk substances that pharmacies may use, a recommendation and not a final decision, as our explainer on why BPC-157 sits outside the pharmacy describes. Wider compounding would put more sterile injectables into the same system that produced this recall. How the FDA balances access against batch-by-batch quality will shape that market more than any single notice. Readers can follow both threads on our safety desk, which tracks compounding rules and the unapproved market.

Conclusion

The compounded tirzepatide recall is narrow: 22 lots, one pharmacy, a Class II rating and no injuries described in the FDA entry. Its weight comes from timing. It reaches the public as Lilly and Novo press their case against copies, as telehealth sellers keep selling them and as the FDA weighs letting pharmacies compound more peptides. The next facts to watch are any inspection findings at the Cary site and whether other compounders report similar problems.